来氟米特联合激素治疗系统性红斑狼疮60例疗效及预后分析

Efficacy and prognosis of leflunomide combined with hormone therapy in 60 patients with systemic lupus erythematosus

目的:探讨来氟米特联合激素治疗系统性红斑狼疮的临床疗效以及安全性。方法:选取系统性红斑狼疮患者60例,按照随机数字表法将其分为两组,对照组与观察组各30例。两组入院后均行常规糖皮质激素治疗,在此基础上,对照组采用环磷酰胺进行冲击治疗,观察组采用来氟米特进行口服治疗,比较两组治疗效果,以及治疗6个月后的24h尿蛋白定量(Uprc),血肌酐(Scr),白细胞计数(WBC),血清白蛋白(ALB),以及狼疮疾病活动指数(SLEDAI),同时对两组治疗期间的不良反应发生情况进行比较。结果:经过相应的药物治疗后,观察组Uprc,ALB,SLEDAI均优于对照组,差异具有统计学意义(P<0.05);对照组治疗有效率为70.00%,观察组治疗有效率为86.67%,观察组优于对照组,差异具有统计学意义(P<0.05)。同时观察组不良反应发生情况优于对照组,差异具有统计学意义(P<0.05)。结论:来氟米特联合激素治疗系统性红斑狼疮的临床疗效显著,安全性高。

Objective： To investigate the clinical efficacy and safety of leflunomide combined with hormone in the treatment of systemic lupus erythematosus （SLE）.Methods： 60 patients with systemic lupus erythematosus were selected and divided into the following groups according to the random number table,the control group （n =30） and the observation group （n =30）.Underwent conventional glucocorticoid treatment in the two groups after admission,on this basis,the control group used cyclophosphamide pulse therapy,observation group were treated with leflunomide for oral treatment,treatment effects were compared between the two groups,and the treatment of 24h urinary protein after 6 months （Uprc）,serum creatinine （Scr）,white blood cell count （WBC）,serum albumin （ALB）,and systemic lupus erythematosus disease activity index （SLEDAI）,while the adverse reactions of two groups during the treatment the incidence were compared.Results：After the drug treatment,the observation group Uprc,ALB,SLEDAI were better than the control group,the difference was statistically significant （P〈0.05）;the control group treatment effective rate was 70%,the effective rate of treatment group was 86.67%,the observation group than the control group,the difference was statistically significant （P〈0.05）.At the same time,adverse reactions in observation group were better than those in control group,the difference was statistically significant （P〈0.05）.Conclusion：Leflunomide combined with hormone treatment of systemic lupus erythematosus clinical efficacy,high safety.